A Phase II placebo-controlled trial of SMT C1100 in Duchenne Muscular Dystrophy patients in US and Europe
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Summit Therapeutics
- 09 Aug 2016 According to Summit Plc media release, planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.
- 05 Feb 2015 New trial record
- 02 Feb 2015 According to Summit Plc media release, this trial is expected to initiate in early 2016.